Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
PUBLISHED: 2015-12-28  877 total views, 1 today

Meng X1, Huang Z2, Teng F1, Xing L3, Yu J4.

Author information

1Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

2Department of Radiology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.

3Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. Electronic address: xinglg@medmail.com.cn.

4Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. Electronic address: sdyujinming@126.com.


Abstract

Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to respond to the PD-1/PD-L1 checkpoint blockades. It is crucial to identify a biomarker to predict the response to checkpoint blockades. The overexpression of PD-L1 is an important and widely-explored predictive biomarker for the response to PD-1/PD-L1 antibodies. However PD-L1 staining cannot be used to accurately select patients for PD-1/PD-L1 pathway blockade due to the low prediction accuracy and dynamic changes. Tumor-infiltrating immune cells and molecules in the tumor microenvironment, or along with PD-L1 expression, may be important in predicting clinical benefits of PD-1/PD-L1 checkpoint blockades. Gene analysis has proven to be new approach for judging the potential clinical benefit of immune checkpoint inhibitors, such as mutational landscape and mismatch-repair deficiency. Further preclinical and clinical studies are necessary to carry out before its application in clinical practice. Challenges should be overcome to identify patients accurately who will benefit from PD-1/PD-L1 checkpoint blockades. In this review, we focus on the predictive biomarkers for checkpoint blockades of PD-1/PD-L1 pathway.


KEYWORDS:

Biomarkers; Immunotherapy; PD-1; PD-L1; Response

Predictive biomarkers in PD-1PD-L1 checkpoint blockade immunotherapy..pdf


Disclaimer: The full text publish has been agreed by the author. This page aims to promote Chinese scientific research. There is no conflicts of interest with any journals reserved the copyright.


Author
Dr. Yu Jinming
+ Author Profile

Dr.  Yu Jinming 

MD, Professor of Surgery, CSCO membership 

Academician of Chinese Academy of Engineering

Honorary President of Shandong Academy of Medical Science

President of Shandong Cancer Hospital &Institute

 

Research Achievement

  • Creatively developed image-guided radiotherapy, biological targeting radiotherapy and many other precise radiotherapy of new technologies. He is one of the pioneers of new technologies and new methods for tumor precise radiotherapy.

  • Presided over anumber of research projects including National 863, National Fifteen, National Eleven Five top research project, and the National Natural Science Foundation Subject of China.

  • Published nearly 500 articles in the domestic and abroad academic journals, in which the"Cancer", "J Nucl Med", "Int J Rad Onc Biol Phys"and other well-known International SCI Journals those included his articles were more than 80.


Email: sdyujinming@126.com


Copyright © 1998 - 2018 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)